Delving into the Latest Updates on Varian Ltd. with Synapse

概览

关联

34

项与 Varian Ltd. 相关的临床试验

NCT06622174 / Not yet recruiting临床1期IIT

Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer (PROMISE) - Phase I Trial

This phase I study aims to evaluate the safety and effectiveness of adaptive pulsed radiotherapy combined with immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC) resistant to immune checkpoint inhibitors. The primary goal is to assess treatment-related toxicity, while secondary objectives include progression-free survival, overall survival, and quality of life. The study will enroll 32 patients.

开始日期2025-04-01

申办/合作机构

Varian Ltd.

NCT06549439 / Not yet recruitingN/AIIT

A Phase I Clinical Study on Feasibility and Toxicity of LINAC-based Flash Radiotherapy for Palliative Treatment of Skin Lesions of Malignant Melanomas

This prospective single center phase I trials aims to assess feasibility and safety of electron FLASH RT for treatment of melanoma skin metastases. Feasibility will be defined as FLASH delivery with an accuracy of +/-10% for each fraction, safety will be confirmed if a maximum of 2 out of 6 patients develop dose limited toxicity.

开始日期2024-12-01

申办/合作机构

University of Zurich

[+1]

NCT06347731 / RecruitingN/A

Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan)

This study is a clinical trial of prospective, single-center, single-arm objective performance criteria. This trial will be conducted with a total of 47 participants enrolled. All participants will be treated with radiation therapy using the medical device of Varian ProBeam360° Proton Therapy System (ProBeam360°), aim to compare the data with objective performance criteria (OPC) to evaluate the effectiveness and safety of ProBeam radiotherapy system for oncology patients, providing a clinical basis for the medical device registration.

开始日期2024-08-29

申办/合作机构

Varian Ltd.

100 项与 Varian Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Varian Ltd. 相关的专利（医药）

登录后查看更多信息

102

项与 Varian Ltd. 相关的文献（医药）

2021-09-07·Novel Optical Systems, Methods, and Applications XXIV

Wavelength- and angle-resolved technique for determining the energy-momentum diagram of photonic systems

作者: Michael Bertilson ; David J. Stowe ; Jonathan Lee

The photonic band structure of plasmonic and nanophotonic materials and devices can be controlled by physical features much smaller than the optical diffraction limit. We present a methodology to correlate nanoscale structure to the photonic band structure directly using the cathodoluminescence (CL) signal generated by a sample in the scanning electron microscope. Further to conventional electron microscope imaging, we record the wavelength- and angular- distributions of luminescence in a highly-parallelized manner. The result is a wavelength- and angle- resolved data cube, which was transformed to observe the emission intensity in the energy-momentum basis revealing the photonic band structure.

2011-10-01·International Journal of Radiation Oncology*Biology*Physics

Dosimetric Comparison of Ir-192 to 50 kV X-rays for Intraoperative Breast Brachytherapy

作者: A. Schroen ; P.W. Read ; M.M. Morris ; B. Libby ; S.H. Benedict ; R. Ter-Antonyan ; J. Morrison ; A. Shoushtari ; D. Brenin

2011-09-01·Journal of the American College of Cardiology1区 · 医学

Cardiorespiratory Response to Exercise After Renal Sympathetic Denervation in Patients With Resistant Hypertension

1区 · 医学

Article

作者: Christine Barth ; Christian Ukena ; Mathias C. Brandt ; Murray Esler ; Michael Böhm ; Felix Mahfoud ; Henry Krum ; Ingrid Kindermann ; Uta C. Hoppe ; Michael Kindermann ; Paul A. Sobotka ; Matthias Lenski

OBJECTIVESThis study sought to investigate the effects of interventional renal sympathetic denervation (RD) on cardiorespiratory response to exercise.BACKGROUNDRD reduces blood pressure at rest in patients with resistant hypertension.METHODSWe enrolled 46 patients with therapy-resistant hypertension as extended investigation of the Symplicity HTN-2 (Renal Denervation With Uncontrolled Hypertension) trial. Thirty-seven patients underwent bilateral RD and 9 patients were assigned to the control group. Cardiopulmonary exercise tests were performed at baseline and 3-month follow-up.RESULTSIn the RD group, compared with baseline examination, blood pressure at rest and at maximum exercise after 3 months was significantly reduced by 31 ± 13/9 ± 13 mm Hg (p < 0.0001) and by 21 ± 20/5 ± 14 mm Hg (p < 0.0001), respectively. Achieved work rate increased by 5 ± 13 W (p = 0.029) whereas peak oxygen uptake remained unchanged. Blood pressure 2 min after exercise was significantly reduced by 29 ± 17/8 ± 15 mm Hg (p < 0.001 for systolic blood pressure; p = 0.002 for diastolic blood pressure). Heart rate at rest decreased after RD (4 ± 11 beats/min; p = 0.028), whereas maximum heart rate and heart rate increase during exercise were not different. Heart rate recovery improved significantly by 4 ± 7 beats/min after renal denervation (p = 0.009). In the control group, there were no significant changes in blood pressure, heart rate, maximum work rate, or ventilatory parameters after 3 months.CONCLUSIONSRD reduces blood pressure during exercise without compromising chronotropic competence in patients with resistant hypertension. Heart rate at rest decreased and heart rate recovery improved after the procedure. (Renal Denervation With Uncontrolled Hypertension; [Symplicity HTN-2]; NCT00888433).

100 项与 Varian Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Varian Ltd. 相关的转化医学

登录后查看更多信息